A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's DiseaseSofia Tzimopoulou, Paul M. Matthews, Brandon Whitcher et al.|Journal of Alzheimer s Disease|2011Cited by 109
IC‐P‐088: Effects of 12 months of treatment with the PPAR<i>γ</i> agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A <sup>18</sup>F‐FDG PET studyEugenii A. Rabiner, Paul M. Matthews, Sofia Tzimopoulou et al.|Alzheimer s & Dementia|2009Cited by 7
P1‐112: Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's Disease: A <sup>18</sup>F‐FDG PET studyEugenii A. Rabiner, Paul M. Matthews, Sofia Tzimopoulou et al.|Alzheimer s & Dementia|2009Cited by 3
Bayesian kinetic modellingRoger N. Gunn, Vincent J. Cunningham, Volker Schmid et al.|NeuroImage|2006Cited by 0